Mane & Steel: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maneandsteel.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide. As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claims concerning compounded semaglutide products appear on your website: • “Clinically Proven Weight Loss” • “Clinically proven GLP-1 therapy to suppress appetite, regulate blood sugar, and accelerate fat loss—trusted by medical professionals worldwide.””

2. 2

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

maneandsteel.com returned a live site on 2026-08-09 titled "MANE & STEEL | Hair Loss Prevention For Men", selling prescription dutasteride hair-loss protocols with account creation. The compounded semaglutide line the letter concerns was not visible on the fetched homepage, which mentioned dutasteride 83 times and semaglutide, GLP-1 and weight loss not at all. The company is operating; the product the letter is about was not on display.

This is the letter to read if you have concluded that the problem in this market is brand-name comparisons. There is no brand here. Neither quoted line mentions Ozempic or Wegovy, neither says "FDA", and neither claims equivalence to anything — they say "clinically proven" and "trusted by medical professionals worldwide". FDA reached the same conclusion it reaches against pages that do name brands. The reason is that clinical proof is what approval represents; a page claiming the proof is claiming the substance of approval without the word. For anyone comparing offers, that is the more useful test. Scanning marketing copy for brand names and "FDA-approved" badges will miss the version of the claim that skips both, and "clinically proven" is doing exactly the same work on the reader. The letter makes no statement about whether the medication is safe or whether it works — only that the trials implied by "proven" were not run on the compounded product being sold.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Mane & Steel failed to respond.